Unknown Manufacturer
ATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process. Unlike protein-derived growth factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and into surrounding tissues.
ATG002 is a completely new approach to treating chronic wounds such as diabetic foot ulcers, which is based upon stimulation of angiogenesis in the wound bed to help drive the wound-healing process. Unlike protein-derived growth factors, ATG002 is a small molecule that, applied topically, effectively penetrates through the wound and into surrounding tissues.
ATG002 is an agonist of the nicotinic acetylcholine (nACh) receptor pathway (pro-angiogenic drugs). It stimulates the nACh receptor pathway and could be useful in promoting angiogenesis in disease conditions where there is an insufficient supply of blood.
Investigated for use/treatment in diabetic foot ulcers and wounds.
